SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission to register for resale previously issued shares of common stock.
As previously announced, Exelixis issued approximately 2.6 million shares of common stock in a private placement on October 18, 2004 in connection with its acquisition of X-Ceptor Therapeutics, Inc. At that time, Exelixis agreed to register the shares of common stock for resale for the benefit of former stockholders of X-Ceptor. Exelixis will not receive any of the proceeds from any resale of the shares of common stock that may be made pursuant to the registration statement.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics across various therapy areas. The company is leveraging its fully integrated gene-to- drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline currently covers cancer and metabolism.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Exelixis which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended September 30, 2004, Exelixis' annual report on Form 10-K for the year ended December 31, 2003, and other filings with the Securities and Exchange Commission.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.
CONTACT: Charles Butler, Associate Director, Corporate Communications ofExelixis, Inc., +1-650-837-7277, or email@example.com